AstraZeneca Pharma India working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

208.32×	208.32×	147.13×	128.34×	167.52×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
31.96×	31.96×	35.94×	36.72×	35.19×
163.79×	163.79×	124.06×	130.82×	210.87×
76.49×	76.49×	59.01×	34.24×	−8.16×
3.24×	3.03×	2.68×	2.25×	1.99×
1.30×	1.30×	1.32×	1.26×	1.09×
−0.08×	−0.08×	0.56×	0.57×	0.59×
−0.06×	−0.06×	0.26×	0.50×	0.35×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

ASTRAZEN₹6,010.00

AstraZeneca Pharma India Limited

· Pharma & Health

₹ CrorePeersSANOFICONR PGHL SANOFI SENORES INNOVACAP MOREPENLAB IOLCP FDCMcap ₹15,025 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Inventory Days (DIO)	167.52	128.34	147.13	208.32	208.32
Receivable Days (DSO)	35.19	36.72	35.94	31.96	31.96
Payable Days (DPO)	210.87	130.82	124.06	163.79	163.79
Cash Conversion Cycle (days)	-8.16	34.24	59.01	76.49	76.49
Working Capital Turnover	1.99	2.25	2.68	3.03	3.24
Asset Turnover	1.09	1.26	1.32	1.30	1.30
Cash Conversion (CFO/Net Income)	0.59	0.57	0.56	-0.08	-0.08
CFO/EBITDA	0.35	0.50	0.26	-0.06	-0.06

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.